Cargando…
Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro
Renal cell carcinoma (RCC) accounts for over 400,000 new cases and 175,000 deaths annually. Diagnostic RCC biomarkers may prevent overtreatment in patients with early disease. Extracellular vesicles (EVs) are a promising source of RCC biomarkers because EVs carry proteins and messenger RNA (mRNA) am...
Autores principales: | Zieren, Richard C., Dong, Liang, Clark, David J., Kuczler, Morgan D., Horie, Kengo, Moreno, Leandro Ferreira, Lih, Tung-Shing M., Schnaubelt, Michael, Vermeulen, Louis, Zhang, Hui, de Reijke, Theo M., Pienta, Kenneth J., Amend, Sarah R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325656/ https://www.ncbi.nlm.nih.gov/pubmed/34331598 http://dx.doi.org/10.1007/s12032-021-01554-2 |
Ejemplares similares
-
A Clinical Radiomics Nomogram Was Developed by Integrating Radiomics Signatures and Clinical Variables to Distinguish High-Grade ccRCC from Type 2 pRCC
por: Gao, Yankun, et al.
Publicado: (2022) -
Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017) -
Functional and translational consequences of immunometabolic coevolution in ccRCC
por: Reznik, Ed, et al.
Publicado: (2023) -
CD44 Is Associated with Poor Prognosis of ccRCC and Facilitates ccRCC Cell Migration and Invasion through HAS1/MMP9
por: Du, Tan, et al.
Publicado: (2023) -
Pivotal biomarker expression and drug screening in advanced ccRCC
por: Xiao, Wen, et al.
Publicado: (2020)